Trade-Ideas LLC identified

Gilead

(

GILD

) as a pre-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified Gilead as such a stock due to the following factors:

  • GILD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $1.1 billion.
  • GILD traded 44,041 shares today in the pre-market hours as of 7:26 AM.
  • GILD is down 3.4% today from yesterday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in GILD with the Ticky from Trade-Ideas. See the FREE profile for GILD NOW at Trade-Ideas

More details on GILD:

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The stock currently has a dividend yield of 1.9%. GILD has a PE ratio of 8. Currently there are 11 analysts that rate Gilead a buy, no analysts rate it a sell, and 5 rate it a hold.

TST Recommends

The average volume for Gilead has been 9.3 million shares per day over the past 30 days. Gilead has a market cap of $132.9 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.16 and a short float of 1.6% with 1.73 days to cover. Shares are down 8.9% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Gilead as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.

Highlights from the ratings report include:

  • The revenue growth came in higher than the industry average of 13.6%. Since the same quarter one year prior, revenues rose by 37.3%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • GILEAD SCIENCES INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, GILEAD SCIENCES INC increased its bottom line by earning $7.38 versus $1.83 in the prior year. This year, the market expects an improvement in earnings ($12.21 versus $7.38).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 68.4% when compared to the same quarter one year prior, rising from $2,731.27 million to $4,600.00 million.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, GILEAD SCIENCES INC's return on equity significantly exceeds that of both the industry average and the S&P 500.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.